SARcode's Dry Eye Drug Hits Endpoint in First Phase III Trial
SARcode Bioscience Inc. cleared the first hurdle in its Phase III program testing dry eye candidate lifitegrast, with the drug nailing its primary endpoint in the first pivotal trial, demonstrating biologic activity against ocular surface damage.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.